IRIS
SIGNORIELLO, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.132
EU - Europa 1.052
AS - Asia 661
SA - Sud America 135
AF - Africa 11
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.996
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.120
IE - Irlanda 405
HK - Hong Kong 280
SG - Singapore 271
IT - Italia 206
GB - Regno Unito 136
BR - Brasile 124
DE - Germania 116
CN - Cina 67
UA - Ucraina 43
GR - Grecia 31
FR - Francia 28
FI - Finlandia 16
SE - Svezia 13
KR - Corea 11
BE - Belgio 10
RU - Federazione Russa 9
CA - Canada 8
TR - Turchia 7
AR - Argentina 6
CZ - Repubblica Ceca 6
HU - Ungheria 6
IN - India 6
AT - Austria 5
IL - Israele 5
NL - Olanda 4
CH - Svizzera 3
MA - Marocco 3
PL - Polonia 3
TN - Tunisia 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
EG - Egitto 2
ES - Italia 2
KE - Kenya 2
MX - Messico 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
VN - Vietnam 2
BG - Bulgaria 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
IQ - Iraq 1
IS - Islanda 1
JO - Giordania 1
KG - Kirghizistan 1
LT - Lituania 1
MD - Moldavia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 2.996
Salva come PNG Salva come JPEG
Città #
Dublin 403
Santa Clara 287
Hong Kong 280
Chandler 148
Singapore 82
Jacksonville 78
Princeton 53
Roxbury 53
Bremen 46
Caserta 41
Naples 34
Ann Arbor 32
New York 31
Cambridge 30
Medford 30
Redhill 26
Munich 24
Beijing 23
Boardman 18
Wilmington 16
Des Moines 13
Los Angeles 13
Aversa 12
Norwalk 12
Milan 11
Seoul 11
São Paulo 11
Brussels 10
Falkenstein 8
Helsinki 8
The Dalles 8
Nanjing 7
Ashburn 6
Nuremberg 6
Redwood City 6
Rome 6
San Mateo 6
Mountain View 5
Rio de Janeiro 5
Cercola 4
Marcianise 4
Nanchang 4
San Giorgio A Cremano 4
Toronto 4
Woodbridge 4
Bari 3
Brno 3
Darmstadt 3
Guarulhos 3
Houston 3
Hyderabad 3
Jinan 3
Lappeenranta 3
Napoli 3
Ottawa 3
Pavia 3
Prague 3
Salto 3
Tianjin 3
Wroclaw 3
Zurich 3
Atibaia 2
Baku 2
Belém 2
Betim 2
Brasília 2
Campinas 2
Casablanca 2
Córdoba 2
Farmington 2
Guangzhou 2
Joinville 2
Lisbon 2
Minsk 2
Nairobi 2
Newark 2
Philadelphia 2
Piemonte 2
Piracicaba 2
Quarto 2
Shenyang 2
Sousse 2
Tel Aviv 2
Uberlândia 2
Volla 2
Wuhan 2
Zhengzhou 2
Acibadem 1
Alajuela 1
Alvorada 1
Amman 1
Ancona 1
Andirá 1
Andover 1
Aracaju 1
Araxá 1
Atlanta 1
Auburn Hills 1
Balneário Gaivota 1
Barbacena 1
Totale 2.036
Salva come PNG Salva come JPEG
Nome #
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 100
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 82
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 75
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 70
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 69
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 69
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 68
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 66
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 65
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families 62
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 59
Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease 58
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. 58
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 57
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 57
Is the pathology of posterior cortical atrophy clinically predictable? 56
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 55
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 55
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 54
Disability assessment using Google Maps 54
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 54
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 53
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 52
Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition 51
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 49
Migraine as possible red flag of PFO presence in suspected demyelinating disease 49
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 49
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity 47
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 47
Clinical activity after fingolimod cessation: disease reactivation or rebound? 47
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 46
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 46
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 46
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series 45
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 45
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 45
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 45
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study 44
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 44
A real-world study of alemtuzumab in a cohort of Italian patients 43
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 43
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 42
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 39
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 39
Integrated cognitive and neuromotor rehabilitation in multiple sclerosis: A pragmatic study 39
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 38
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 35
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 34
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. 34
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab 33
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis 33
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 33
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 32
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 31
Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. 31
Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study 29
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 29
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 29
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report 28
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 26
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 23
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 22
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 20
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 19
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 19
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 18
Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood 18
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 17
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue 16
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 15
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis 14
Signs and symptoms of COVID-19 in patients with multiple sclerosis 14
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) 13
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 13
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 12
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 12
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 11
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 8
Totale 3.197
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.448
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.448
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 0 0 0 18 6
2020/2021193 29 2 7 9 24 1 34 13 9 21 33 11
2021/2022422 13 38 3 12 99 7 10 8 30 50 25 127
2022/2023701 72 18 9 45 79 42 0 35 353 6 23 19
2023/2024376 23 11 22 21 107 41 33 5 8 3 24 78
2024/20251.197 2 22 8 47 210 194 150 125 228 208 3 0
Totale 3.197